Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: The scale sleep apnea randomized clinical trial Academic Article uri icon

Overview

MeSH Major

  • Health Care Costs
  • Overweight
  • Waist Circumference

abstract

  • As an adjunct to diet and exercise, liraglutide 3.0 mg was generally well tolerated and produced significantly greater reductions than placebo in AHI, body weight, SBP and HbA1c in participants with obesity and moderate/severe OSA. The results confirm that weight loss improves OSA-related parameters.

publication date

  • August 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4973216

Digital Object Identifier (DOI)

  • 10.1038/ijo.2016.52

PubMed ID

  • 27005405

Additional Document Info

start page

  • 1310

end page

  • 9

volume

  • 40

number

  • 8